• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌的特征:增殖与细胞生长。

The hallmarks of ovarian cancer: proliferation and cell growth.

作者信息

López-Reig Raquel, López-Guerrero José Antonio

机构信息

Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.

IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), 46012 Valencia, Spain.

出版信息

EJC Suppl. 2020 Aug 22;15:27-37. doi: 10.1016/j.ejcsup.2019.12.001. eCollection 2020 Aug.

DOI:10.1016/j.ejcsup.2019.12.001
PMID:33240440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7573473/
Abstract

Epithelial ovarian cancer (EOC) is a heterogeneous group of diseases with distinct biological and clinical behaviour. Despite the differences between them, the capability of tumour cells to continuously proliferate and avoid death is maintained among histotypes. This ability is the result of alterations at different levels, causing the deregulation of cell cycle and proliferative-related pathways. Even if the leading role is played by RB and TP53, changes in other molecular pathways are involved in the development of EOC. This ability can be exploited to generate and models resembling the conditions of tumour development in a patient. models, such as patient-derived xenografts (PDX) or genetically engineered mouse models (GEMM), represent a fundamental tool in the study of the molecular mechanisms implicated in each EOC biotype for testing new therapeutic approaches. Herein we describe the major proliferation-related pathways and its disruption found in EOC and how these features can be used to establish models for translational research.

摘要

上皮性卵巢癌(EOC)是一组具有不同生物学和临床行为的异质性疾病。尽管它们之间存在差异,但在不同组织学类型中,肿瘤细胞持续增殖和避免死亡的能力是保持的。这种能力是不同水平改变的结果,导致细胞周期和增殖相关途径的失调。即使RB和TP53起主要作用,但其他分子途径的改变也参与了EOC的发展。这种能力可被用于生成类似于患者肿瘤发展情况的模型。患者来源的异种移植(PDX)或基因工程小鼠模型(GEMM)等模型是研究每种EOC生物型所涉及的分子机制以测试新治疗方法的基本工具。在此,我们描述了在EOC中发现的主要增殖相关途径及其破坏情况,以及如何利用这些特征建立用于转化研究的模型。

相似文献

1
The hallmarks of ovarian cancer: proliferation and cell growth.卵巢癌的特征:增殖与细胞生长。
EJC Suppl. 2020 Aug 22;15:27-37. doi: 10.1016/j.ejcsup.2019.12.001. eCollection 2020 Aug.
2
The promise and challenge of ovarian cancer models.卵巢癌模型的前景与挑战。
Transl Cancer Res. 2015 Feb;4(1):14-28. doi: 10.3978/j.issn.2218-676X.2015.01.02.
3
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.上皮性卵巢癌的临床前模型:实际考虑因素及有意义应用的挑战。
Cell Mol Life Sci. 2022 Jun 16;79(7):364. doi: 10.1007/s00018-022-04395-y.
4
miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.微小RNA-211通过靶向细胞周期蛋白D1和细胞周期蛋白依赖性激酶6抑制上皮性卵巢癌的增殖和细胞周期进程。
Mol Cancer. 2015 Mar 11;14:57. doi: 10.1186/s12943-015-0322-4.
5
MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.微小RNA-222-3p/鸟嘌呤核苷酸结合蛋白α抑制性多肽2/蛋白激酶B轴抑制上皮性卵巢癌细胞生长并与良好的总生存率相关。
Oncotarget. 2016 Dec 6;7(49):80633-80654. doi: 10.18632/oncotarget.13017.
6
Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice.溶血磷脂酸可刺激免疫活性小鼠的细胞迁移、侵袭、集落形成以及小鼠卵巢癌的肿瘤发生/转移。
Mol Cancer Ther. 2009 Jun;8(6):1692-701. doi: 10.1158/1535-7163.MCT-08-1106. Epub 2009 Jun 9.
7
Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer.胶原蛋白三螺旋重复序列 1 蛋白(CTHRC1)激活整合素 β3/FAK 信号通路并促进卵巢癌转移。
J Ovarian Res. 2017 Oct 11;10(1):69. doi: 10.1186/s13048-017-0358-8.
8
Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.吡哆醛 5'-磷酸氧化酶是上皮性卵巢癌中 TGF-β 信号通路调控的一个新的治疗靶点。
Cell Death Dis. 2017 Dec 13;8(12):3214. doi: 10.1038/s41419-017-0050-3.
9
Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.上皮性卵巢癌中FOXM1过表达的遗传决定因素及其对细胞周期进程的功能作用。
Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.
10
Novel Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research.上皮性卵巢癌的新型模型:生物标志物与治疗研究的未来
Front Oncol. 2022 Mar 25;12:837233. doi: 10.3389/fonc.2022.837233. eCollection 2022.

引用本文的文献

1
Expression profiling of KRAS and NOXA genes as prospective biomarkers in ovarian carcinoma.KRAS和NOXA基因作为卵巢癌潜在生物标志物的表达谱分析。
Sci Rep. 2025 Sep 5;15(1):32370. doi: 10.1038/s41598-025-17650-6.
2
Competing endogenous RNA networks in ovarian cancer: from bench to bedside.卵巢癌中的竞争性内源性RNA网络:从实验台到病床边
EXCLI J. 2025 Jan 7;24:86-112. doi: 10.17179/excli2024-7827. eCollection 2025.
3
Could cannabinoids provide a new hope for ovarian cancer patients?大麻素类药物能否为卵巢癌患者带来新希望?

本文引用的文献

1
Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance.Wnt信号通路在卵巢癌干性、上皮-间质转化及治疗耐药中的作用
J Clin Med. 2019 Oct 11;8(10):1658. doi: 10.3390/jcm8101658.
2
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.PI3K/AKT/mTOR 信号通路在卵巢癌中的作用:生物学和治疗意义。
Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22.
3
RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression.
Pharmacol Res Perspect. 2023 Aug;11(4):e01122. doi: 10.1002/prp2.1122.
4
Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.基于分子的子宫内膜间质肉瘤诊断免疫组化算法。
Mod Pathol. 2023 Apr;36(4):100084. doi: 10.1016/j.modpat.2022.100084. Epub 2023 Jan 10.
5
Molecular Management of High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的分子管理
Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
6
Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma.异常的丝裂原活化蛋白激酶信号传导为卵巢癌的治疗提供了治疗潜力。
Onco Targets Ther. 2022 Nov 5;15:1331-1346. doi: 10.2147/OTT.S361512. eCollection 2022.
7
Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.增强 ZNF521 的表达可诱导人卵巢癌细胞系呈现侵袭表型。
PLoS One. 2022 Oct 3;17(10):e0274785. doi: 10.1371/journal.pone.0274785. eCollection 2022.
8
RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer.液体活检中来自肿瘤附近部位的 RNA 生物标志物用于卵巢癌的诊断。
Neoplasia. 2022 Feb;24(2):155-164. doi: 10.1016/j.neo.2021.12.008. Epub 2022 Jan 5.
RAS/MAPK信号传导在氧化应激、DNA损伤反应和癌症进展中发挥作用。
J Cell Physiol. 2019 Sep;234(9):14951-14965. doi: 10.1002/jcp.28334. Epub 2019 Feb 27.
4
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.Notch3靶向治疗:对抗卵巢癌干细胞的新型武器。
Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019.
5
Tumor metabolism regulating chemosensitivity in ovarian cancer.肿瘤代谢对卵巢癌化疗敏感性的调节作用
Genes Cancer. 2018 May;9(5-6):155-175. doi: 10.18632/genesandcancer.176.
6
Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.靶向细胞周期蛋白依赖性激酶治疗妇科癌症
Front Oncol. 2018 Aug 8;8:303. doi: 10.3389/fonc.2018.00303. eCollection 2018.
7
How the Warburg effect supports aggressiveness and drug resistance of cancer cells?Warburg 效应如何支持癌细胞的侵袭性和耐药性?
Drug Resist Updat. 2018 May;38:1-11. doi: 10.1016/j.drup.2018.03.001. Epub 2018 Mar 20.
8
A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.用于临床前测试的具有基因组特征的高级别浆液性卵巢癌异种移植物集合。
Am J Pathol. 2018 May;188(5):1120-1131. doi: 10.1016/j.ajpath.2018.01.019. Epub 2018 Feb 16.
9
PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.PGC-1α 促进乳腺癌转移并赋予代谢药物的生物能量灵活性。
Cell Metab. 2017 Nov 7;26(5):778-787.e5. doi: 10.1016/j.cmet.2017.09.006. Epub 2017 Oct 5.
10
Mutational heterogeneity in non-serous ovarian cancers.非浆液性卵巢癌中的突变异质性。
Sci Rep. 2017 Aug 29;7(1):9728. doi: 10.1038/s41598-017-10432-9.